CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 496 enrolled
Drug / intervention
APL-130277drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02542696
NCT02542696Phase 3Completed
CompareCT.gov

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Sumitomo Pharma America, Inc.·interventional·Posted Sep 7, 2015·Updated Nov 22, 2023

In Brief

A Phase 3 clinical trial evaluating APL-130277 for Parkinson Disease. Completed, enrolled 496 participants across 70 sites in 8 countries.

Detailed Summary

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesAustria, Canada, France, Germany, Italy, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 7, 2015
Enrollment StartAug 31, 2015
Primary CompletionNov 8, 2022
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 10.8 years ago

Interventions

APL-130277drug

Used to treat up to 5 "OFF" episodes per day